The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

Region Genetic Association Analysis of Breast Cancer Patients With and Without Persistent Postsurgical Neuropathic Pain,” ...

The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ANOC-001 in Advanced Pancreatic Cancer at leading medical centres in Sweden ...

How to decide who should be prioritized for the Covid vaccine? And how to determine who is more likely to develop the disease in its most severe form, leading to death? And why did the pandemic ...

Several studies have suggested that COVID-19 may increase a person’s risk of developing cancer or promote metastasis of existing cancer.

TScan Therapeutics is developing TSC-101 and multiplex TCR-Ts for cancer treatment. See why TCRX stock holds potential with ...

Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66th ASH Annual Meeting and ExpositionIND application cleared for seventh ...

We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...

When you’re diagnosed with brain cancer, learning as much as you can about it can help you choose the best treatment for you. This guide shows you the basics on the types of brain cancer and how ...

“The use of posttransplant cyclophosphamide over the last two decades to prevent graft rejection and [graft-versus-host disease], initially in patients with cancer, has allowed the successful ...